Current treatment guidelines highlight the importance of lipid-lowering therapy in reducing cardiovascular risk in patients with type 2 diabetes. Statins have been shown to be effective in reducing cardiovascular risk in patients with diabetes, but they fail to address adequately the coronary risk associated with low plasma levels of high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides, commonly reported in these patients. Fibrates are effective against all three components of the atherogenic dyslipidaemic profile that characterises type 2 diabetes.
Clinical studies such as the Veterans Affairs HDL Intervention Trial (VA-HIT), which showed a marked and statistically significant reduction in coronary heart disease death and stroke, as well as the Diabetes Atherosclerosis Intervention Study (DAIS), which showed that treatment with fenofibrate produced significantly less progression in markers of focal coronary artery disease, support a role for fibrate therapy in cardiovascular risk reduction in type 2 diabetes. Together, these data provided the rationale for the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, the largest study to date in patients with type 2 diabetes.
1. Chapman MJ.Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis2003;171:1–13.
2.
2. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP. Expert Panel on detection, evaluation, and treatment of high blood pressure in adults (Adult Treatment Panel III). JAMA2001;285:2486–97.
3.
3. International Atherosclerosis Society. Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. Available from http://www.athero.org.
4.
4. American Diabetes Association. Dyslipidaemia management in adults with diabetes. Diabetes Care2004;27(suppl 1):S68–S71.
5.
5. Colhoun HM, Betteridge DJ, Durrington PNet al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685–96.
6.
6. Knopp RH, D'Emden M, Smilde JGet al.Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care2006;29:1478–85.
7.
7. Wanner C, Krane V, Marz Wet al.Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med2005;353: 238–48.
8.
8. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes. The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905–10.
9.
9. The FIELD study investigator. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849–61.
10.
10. Baigent C, Keech A, Kearney PMet al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet2005;366:1267–78.
11.
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart diseas. the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344:1383–9.
12.
12. Pyörälä K, Pedersen TR, Kjekshus Jet al.Cholesterol lowering with simvastatin improves prognosis of diabetic patents with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997;20:614–20.
13.
13. Haffner SM, Alexander CM, Cook TJet al.Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med1999;159:2661–7.
14.
14. Goldberg RB, Mellies MJ, Sacks FMet al.Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. Circulation1998;98:2513–19.
15.
15. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998;339:1349–57.
16.
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005–16.
17.
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA2002;288:2998–3007.
18.
18. Sever PSS, Dahlöf B, Poulter Net al.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003;361:1149–58.
19.
19. Sever PS, Poulter NR, Dahlöf Bet al.Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes. Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care2005;28:1151–7.
20.
20. Ballantyne CM, Herd A, Ferlic LLet al.Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation1999;99:736–43.
21.
21. Sacks FM for the Expert Group on HDL cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol2002;90:139–43.
22.
22. Pfeffer MA, Sacks FM, Moyé LAet al.Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. J Am Coll Cardiol1999;33:125–30.
23.
23. Birjmohun RS, Hutten BA, Kastelein JJPet al.Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol2005;45:185–97.
24.
24. Feher MD, Caslake M, Foxton Jet al.Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev1999;15:395–9.
25.
25. Vakkilainen J, Steiner G, Ansquer JCet al.Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation2003;107:1733–7.
26.
26. Frick MH, Elo O, Haapa Ket al.Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med1987;317:1237–45.
27.
27. Koskinen P, Mantarri M, Manninen Vet al.Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care1992;15:820–5.
28.
28. Tenkanen L, Mänttäri M, Kovanen PTet al.Gemfibrozil in the treatment of dyslipidaemia. An 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med2006;166:743–8.
29.
29. Rubins HB, Robins SJ, Collins Det al.Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med2002;162:2597–604.
30.
30. Arcavi L, Behar S, Caspi Aet al.High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study. Am Heart J2004;147:239–45.
